Metabolic Peptides: Mitochondrial Health & Metabolism Research
Metabolic peptides like MOTS-c represent an emerging area of research focused on cellular energy metabolism and mitochondrial function. MOTS-c, a mitochondrial-derived peptide, has been studied for its role in glucose homeostasis and exercise mimetic effects.
This category includes compounds at the intersection of metabolism, aging, and cellular health research. MOTS-c is one of several mitochondrial-derived peptides discovered in the last 15 years, and preclinical evidence suggests effects on insulin sensitivity, exercise capacity, and metabolic flexibility in animal models. Human trial data is preliminary. This category overlaps significantly with weight loss peptides (GLP-1 agonists act on metabolism too) and longevity peptides. For patients with confirmed metabolic conditions (type 2 diabetes, metabolic syndrome), FDA-approved therapies have dramatically stronger evidence than research peptides. Metabolic peptide use outside validated indications should be considered experimental.
6 compounds in this category
Key Takeaways
- MOTS-c is a mitochondrial-derived peptide with preclinical metabolic data
- Human clinical trial evidence is preliminary
- FDA-approved GLP-1 agonists have dramatically stronger metabolic evidence
- Not a substitute for standard diabetes or metabolic syndrome treatment
- Long-term safety data is limited across the category
Compounds in This Category
SemaglutideOzempic, Wegovy
An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management.
TirzepatideMounjaro, Zepbound
An FDA-approved dual GIP/GLP-1 receptor agonist that has shown the highest weight loss results of any approved medication.
TesamorelinEgrifta, TH9507
An FDA-approved GHRH analog used for HIV-associated lipodystrophy, with research into broader metabolic and cognitive applications.
RetatrutideLY3437943, Triple Agonist
A triple-acting GIP/GLP-1/glucagon receptor agonist in Phase 3 trials showing potentially the highest weight loss of any drug in development.
MOTS-cMitochondrial Open Reading Frame of the 12S rRNA-c
A mitochondria-derived peptide that targets the AMPK pathway, studied for metabolic regulation and exercise mimicry.
NAD+Nicotinamide Adenine Dinucleotide, NAD
A coenzyme critical for cellular energy and DNA repair. Not technically a peptide, but commonly discussed alongside peptide therapies in the longevity space.
Frequently Asked Questions
Does MOTS-c improve insulin sensitivity?
Animal studies suggest improvements in insulin sensitivity and glucose homeostasis. Human trial data is preliminary and not yet sufficient for clinical recommendations.
Can metabolic peptides replace diabetes medications?
No. FDA-approved diabetes therapies have far stronger evidence. Research peptides should not substitute for standard-of-care diabetes management.
Is MOTS-c an "exercise mimetic"?
Preclinical data shows some exercise-like metabolic effects, but the label "exercise mimetic" overstates what has been demonstrated in humans.
How is MOTS-c administered?
Typically via subcutaneous injection. Oral formulations have poor bioavailability.
What are the side effects?
Limited human data makes comprehensive side-effect profiling impossible. Injection-site reactions and unknown long-term effects are the main concerns.